SCHEHLMANN et al U.S. National Phase of PCT/EP2005/003115

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (original) Composition comprising at least one HDAC inhibitor in combination with a retinoid and a cosmetically or pharmaceutically acceptable excipient or diluent.
- 2. (original) Composition according to claim 1, wherein the HDAC inhibitor is a compound of the formula

wherein

R is hydrogen or a C_1 - C_{30} hydrocarbon residue and n is an integer of 1 to 5.

- 3. (original) Composition according to claim 2, wherein R is hydrogen, a C₄-C₂₀ alkyl group or a C₄-C₂₀ alkenyl group.
- 4. (currently amended) Composition according to any of claims 1 to 3 claim1, wherein the retinoid is a compound of the formula

SCHEHLMANN et al U.S. National Phase of PCT/EP2005/003115

wherein R⁶ and R⁷ are independently of each other hydrogen or hydroxy or R⁶ and R⁷ together form an oxygen atom

R⁸ and R⁹ are hydrogen or R⁸ and R⁹ together form an oxygen atom R¹⁰ is hydrogen, hydroxy or a residue OR¹¹

 R^{11} is C_1 - C_{20} alkyl (preferably C_1 - C_6 alkyl), C_2 - C_{20} alkenyl (preferably C_2 - C_6 alkenyl), C_6 - C_{20} aryl, C_7 - C_{20} alkylaryl or a residue -C(O)- R^{12}

R¹² is C₁-C₂₀ alkyl (preferably C₁-C₆ alkyl) or C₂-C₂₀ alkenyl (preferably C₂-C₆ alkenyl).

- 5. (currently amended) Composition according to any of claims 1 to 4 claim 1, which is a topical composition.
- 6. (currently amended) Composition according to any of claims 1 to 5 claim 1, wherein the composition contains the HDAC inhibitor in a concentration of 0.001 to 50 wt.-%, based on the weight of the composition.
- 7. (original) Composition according to claim 6, wherein the HDAC inhibitor is present in a concentration of 0.01 to 1 wt.-%, based on the weight of the composition.
- 8. (currently amended) Composition according to any of claims 1 to 7 claim 1, wherein the retinoid is present in a concentration of 0.001 to 50 wt.-%, based on the weight of the composition.
- 9. (original) Composition according to claim 8, wherein the retinoid is present in a concentration of 0.1 to 15 wt.-%, based on the weight of the composition.
- 10. (currently amended) Composition according to any of claims 1 to 9 claim 1, wherein the ratio of the HDAC inhibitor to the retinoid is from 30:1 to 1:30, based on the weight.

SCHEHLMANN et al U.S. National Phase of PCT/EP2005/003115

- 11. (currently amended) Composition according to any of claims 1 to 10 claim 1, which is a cosmetic composition.
- 12. (original) Use of a combination of an HDAC inhibitor and a retinoid for the preparation of a composition for providing a cosmetic effect.
- 13. (original) Use according to claim 12, wherein the cosmetic effect is treatment or prophylaxis of wrinkles or dry skin or sensitive skin or any symptoms caused by negative developments of the physiological homeostasis of healthy skin, promotion of hair growth, protection from hair loss, a thickening of the epidermis, anti-acne, the inhibition of senesence of skin cells, prevention or treatment of photodamage, prevention or treatment of oxidative stress phenomena, prevention or treatment of cellulite, prevention or treatment of pigmentation disorders and/or even the skin tone, prevention and treatment of disturbances in ceramide and lipid synthesis, prevention of excess sebum production, reduction of activities of matrix metallo proteases or other proteases in the skin, treatment and prevention of inflammatory skin conditions including atopic eczema, polymorphic light eruption, psoriasis, vertiligo, prevention and treatment of itchy or irritated skin.